Chief Judge Gregory M. Sleet recently construed claim terms relating to pharmaceutical pellets for the treatment of irritable bowel syndrome. Salix Pharmaceuticals, Inc., et al. v. Lupin Ltd., et al., C.A. No. 12-1104-GMS (D. Del. Dec. 17, 2013). The Court first adopted the parties’ joint proposed construction of the claim terms “pellet” and “mean maximal plasma concentration of the 5-aminosalicyclic acid is reached at”. The Court then construed the following disputed claim terms: “matrix-forming polymer”; “non gel-forming polymer matrix”; and “polymer matrix”; “homogeneously dispersed”; and “about 4 hours”, giving the latter two their plain and ordinary meanings.